The older of a pair of sisters experienced hypoglycemia after the start of thiamazole (MMI) treatment. Based on a high insulin antibody level, she was diagnosed with insulin autoimmune syndrome (IAS). HLA-DNA typing identified DRB1*04:06. Although a 75-g oral glucose tolerance test (OGTT) showed biphasic insulin secretion, the secretion pattern became monophasic after discontinuation of the MMI. The younger sister was diagnosed with IAS after the start of MMI treatment. HLA-DNA typing identified DRB1*04:06. The 75-g OGTT showed biphasic insulin secretion, but it became monophasic after discontinuation of the MMI. According to the similar insulin secretion kinetics in the two sisters with IAS, we suspect that a genetic predisposition may be associated with the features of anti-insulin antibodies.
Introduction
Insulin autoimmune syndrome (IAS) was first reported by Hirata et al. (1) . Human leukocyte antigen (HLA) DRB1* 04:06 and the use of sulfhydryl (SH)-containing drugs are strongly involved in the onset of IAS (2, 3) . The affinity of anti-insulin antibodies is evaluated by a Scatchard analysis, and is known to vary widely and to be involved in the clinical course and onset of hypoglycemia (4, 5) . However, which factors contribute to the various features of antiinsulin antibodies remains elusive.
We encountered siblings who developed IAS. The two sisters had similar insulin secretion kinetics, suggesting an association between a genetic predisposition and the features of anti-insulin antibodies. The present cases are considered valuable, especially with the paucity of information on siblings with IAS.
Immunoreactive insulin (IRI) levels were measured by a chemiluminescence immunoassay using Chemilumi Insulin (Kyowa Medex, Tokyo, Japan) (reference range: 2.2-12.4 μU/mL) in the older sister and by a chemiluminescence enzyme immunoassay using Lumipulse Presto Insulin (Fujirebio Inc., Tokyo, Japan) (reference range: 1.84-12.20 μU/mL) in the younger sister. The methods for measuring IRI differed between the two sisters due to an alteration in the methods employed. Serum insulin antibody levels were measured by a radioimmunoassay using the Cosmic insulin antibody (Cosmic, Tokyo, Japan). HLA-DNA typing was conducted by polymerase chain reaction sequence-based typing using the Allele SEQR HLA-DRB1 (Abbott Japan, Tokyo, Japan) and the QIAamp DNA Blood BioRobot9604 Kit (Qiagen N.V., Venlo, the Netherlands). September, her thyroid function had improved, as indicated by a TSH level of <0.1 μIU/mL and FT4 of 0.5 ng/dL, allowing a reduction in the MMI dose to 20 mg/day. However, the patient developed general malaise without a trigger during the same period, for which she was admitted to a local hospital. She had no history of insulin therapy or the use of dietary supplements.
The physical findings on admission included height, 159 cm; weight, 78 kg [body mass index (BMI), 30.8 kg/m 2 ]; blood pressure, 109/69 mmHg; pulse rate, 75 beats/min; and clear consciousness. Diffuse goiter was observed, but there was no exophthalmos, eye retraction or lid lag. No abnormalities were detected on chest and cardiac auscultation. The neurological findings were normal.
Of the laboratory tests performed on admission (Table 1) , the liver and renal function test results were normal and no electrolyte abnormalities were detected. The fasting plasma glucose level was 86 mg/dL and the blood IRI level was 15.1 μU/mL. The postprandial plasma glucose level was 59 mg/dL, indicating hypoglycemia. Because the titer of antiinsulin autoantibody was high at 51.5% (Fig. 1) , she was diagnosed with IAS. A 75-g oral glucose tolerance test (OGTT) showed biphasic glucose-insulin kinetics, while insulin hypersecretion was detected after oral glucose loading (Fig. 2) . HLA-DNA typing identified DRB1*04:05 and DRB1*04:06, which is characteristic of IAS.
Because the MMI was the presumed cause of the IAS, it was discontinued after admission. This resulted in disappearance of the hypoglycemic attacks. The insulin antibody level was 24.9% in October and normalized to 6.3% in December (Fig. 1) . Later, the patient underwent subtotal thyroidectomy at the Department of Endocrine Surgery. Laboratory tests performed in August X+1 showed a normal titer of antiinsulin autoantibody (4.7%) with normal levels of fasting plasma glucose (91 mg/dL) and blood IRI (8 μU/mL). Moreover, a repeat 75-g OGTT showed mono-phasic glucose-insulin kinetics and no insulin hypersecretion (Fig. 2) .
Case 2 (younger sister)
A 29-year-old woman experienced palpitations, tremors and weight loss in January Y. She was diagnosed with GD, with the following laboratory test results: TSH <0.1 μIU/ mL; FT4, 2.14 ng/dL; and TSH receptor antibody level, 7.8 IU/L. Treatment was started with 100 mg/day of potassium iodide. However, 30 mg/day of MMI was added to the treatment in August of the same year due to a recurrence of the GD. The patient developed ophthalmic manifestations in September and was admitted to our department in November for further management of thyroid-associated ophthalmopathy. She had no history of insulin therapy or the use of dietary supplements.
A physical examination on admission showed height, 166 cm; weight, 66.5 kg (BMI, 24.2 kg/m 2 ); blood pressure, 106/70 mmHg; pulse rate, 68 beats/min; and clear consciousness. Diffuse goiter, exophthalmos and eye retraction were observed. No abnormalities were detected on chest and cardiac auscultation and the neurological findings were normal.
Laboratory tests performed on admission (Table 2) showed normal liver and renal function test results and no electrolyte abnormalities. We decided to use a wait-and-see approach regarding the thyroid-associated ophthalmopathy since it was inactive.
Because the older sister had already been diagnosed with IAS, she underwent a detailed examination for IAS. The fasting plasma glucose level was 86 mg/dL and the blood IRI level was 15.1 μU/mL. Based on the high titer of antiinsulin autoantibody (59.8%, Fig. 3) , she was diagnosed with IAS. A 75-g OGTT showed biphasic glucose-insulin kinetics (Fig. 4) . HLA-DNA typing identified DRB1*04:06, which is characteristic of IAS, and DRB1*09:01:02.
Although the dose of MMI was reduced to 15 mg/day, 
T i m e (m i n u t e s)
the IRI and insulin antibody levels were still high in December at 9.6 μU/mL and 41.9%, respectively. A subtotal thyroidectomy was performed the following February Y+1. In October of the same year, the titer of anti-insulin autoantibody was normalized at 3.7%, while the fasting plasma glucose and blood IRI levels were improved to 87 mg/dL and 7.2 μU/mL, respectively. A repeat 75-g OGTT performed in December showed monophasic glucose-insulin kinetics (Fig. 4) .
Discussion
IAS is common in Japan, and to date, approximately 380 cases have been reported (6) . To the best of our knowledge, however, there are no reports of IAS in siblings, so our cases represent the first of siblings with IAS to be reported. We suspect that a genetic predisposition might be associated with the features of anti-insulin antibodies based on the similar insulin secretion kinetics in the two sisters with IAS.
Genetic and environmental factors are considered to play important pathogenic roles in IAS. Uchigata et al. (7) found the DR4 HLA type in 96% of Japanese patients with IAS and the DRB1*04:06 DNA type in 84%, suggesting that these alleles play important roles in IAS. The environmental factors that trigger IAS include MMI, tiopronin, glutathione and α-lipoic acid, which contain an SH group (8, 9) . On the other hand, there is no information on the factors responsible for the features of anti-insulin antibodies. While their features are evaluated by a Scatchard analysis, the affinity of anti-insulin antibodies varies widely and is reportedly associated with the onset of hypoglycemia (4, 5) and the insulin secretion kinetics (10). In both of our patients, the clinical courses and insulin secretion kinetics determined by the 75-g OGTT were similar. This suggests the production of similar anti-insulin antibodies, and it was assumed that genetic factors are also associated with the features of anti-insulin antibodies.
According to the reports on Scatchard analyses of this syndrome, insulin antibodies are polyclonal and have a dissociation constant at the high-affinity site that is significantly lower than that of insulin antibodies produced by insulin injection (11, 12) . In typical IAS associated with insulin antibodies with low affinity and high binding capacity, hypoglycemia is the cardinal symptom. However, hyperglycemia is likely to occur after a meal, and the insulin secretion kinetics determined by a 75-g OGTT is considered characteristically to exhibit marked hyperinsulinemia in a monophasic pattern (10) . In our patients, the severity of the hypoglycemic attacks was mild and the 75-g OGTT showed biphasic insulin secretion kinetics unlike typical IAS. Thus, we suspect that the features of anti-insulin antibodies in our patients differed from those described for typical IAS. Unfortunately, we did not analyze the affinity of such antibodies by a Scatchard analysis in our patients.
In summary, we herein reported our experience in the treatment of two sisters who developed IAS during an MMI treatment for GD. We suspect that a genetic predisposition might be associated with the features of anti-insulin antibodies, as evidenced by the similar insulin secretion kinetics in the two sisters.
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